Abstract:Proteolysis-targeting chimeras (PROTACs) are essential bifunctional molecules that target proteins of interest (POIs) for degradation by cellular ubiquitination machinery. Despite significant progress made in understanding PROTACs' functions, their therapeutic potential remains largely untapped. As a result of the success of highly flexible, scalable, and low-cost mRNA therapies, as well as the advantages of the first generation of peptide PROTACs (p-PROTACs), we present for the first time an engineering mRNA PROTACs (m-PROTACs) strategy. This design combines von Hippel-Lindau (VHL) recruiting peptide encoding mRNA and POI-binding peptide encoding mRNA to form m-PROTAC and promote cellular POI degradation. We then performed proof-of-concept experiments using two m-PROTACs targeting two cancer-related proteins, estrogen receptor alpha and B-cell lymphoma-extra large protein. Our results demonstrated that m-PROTACs could successfully degrade the POIs in different cell lines and more effectively inhibit cell proliferation than the traditional p-PROTACs. Moreover, the in vivo experiment demonstrated that m-PROTAC led to significant tumor regression in the 4T1 mouse xenograft model. This finding highlights the enormous potential of m-PROTAC as a promising approach for targeted protein degradation therapy. We developed mRNA proteolysis-targeting chimeras (PROTACs), a novel type of PROTACs, which incorporate mRNAs encoding E3 ligase recruiting peptide ligand and protein of interest (POI)-binding peptide ligand to promote cellular POI degradation. For the first time, we demonstrated that the encoding peptide PROTACs could degrade POIs and inhibit cell proliferation more effectively than the traditional peptide PROTACs, indicating their tremendous potential for targeted protein degradation therapy. image

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

Phase Separation Enhanced PROTAC for Highly Efficient Protein Degradation

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

An overview of PROTACs: a promising drug discovery paradigm

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]